SEP 21·SEC EDGARLow
Rogers Campbell sold $987K of HTFL
Rogers Campbell (Chief Medical Officer) sold 19,682 shares of Heartflow, Inc. (HTFL) at $50.15 ($0.99M total) on 2026-09-18 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · HEALTH INFORMATION SERVICES
$HTFL
Heartflow, Inc.
AlphAI earnings readSecond Quarter 2026 · AUG 13Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 GuidanceVerdict: strongRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $HTFLvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $HTFL in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $7.5M 10 txs
Verghese Vikram7× · $4.7M
10b5-1 share of filings100%
Top stories · $HTFLMore →
SEP 21·rttnews.com
Biotech Stocks At 52-Week Highs - HSCS +7%, FRNM +5%, VOGX, HTFL, HALO
Several biotech stocks reached 52-week highs on September 18, 2026. Vogenx (VOGX) shares surged to $38.41, driven by positive clinical trial results. HeartSciences (HSCS) rose 7% to $5.21, while HeartFlow (HTFL) increased 2% to $52.22. Freenome (FRNM) gained 5% to $17.25, and Halozyme (HALO) hit $112.66 after announcing a $1.3B offering.
SEP 19·uk.investing.com
Heartflow CFO Verghese sells over $1.2 million in company stock
HeartFlow CFO Vikram Verghese sold 24,345 shares worth $1.23M in two transactions, under a 10b5-1 plan, with shares trading near 52-week high. HeartFlow reported Q2 2026 revenue of $64.1M, up 48% YoY, and narrowed loss. Stifel raised its price target to $45, maintaining a Buy rating.
HTFL sentiment & insider activity
Recent HTFL coverage spans insider activity, financial news and market movers.
In the last 30 days, HTFL insiders filed 10 SEC Form 4 transactions — no purchases and 10 sales ($7.5M). The most active reporter was Verghese Vikram, Chief Financial Officer, with 7 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving HTFL
Insider sale may signal reduced confidence or portfolio rebalancing, potentially pressuring HTFL price.
Revenue growth and clinical validation may offset loss concerns, keeping the stock attractive.
Insider sale may signal reduced confidence, potentially pressuring the stock lower.
Insider sale may signal reduced confidence or portfolio rebalancing, potentially pressuring the stock short term.
Potential negative sentiment from insider sell may pressure HTFL price short term.
AlphAI scores every news story that mentions HTFL with an AI model for sentiment and relevance, and aggregates insider trades from Heartflow, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $HTFL
Score
Rogers Campbell sold $987K of HTFL
Rogers Campbell (Chief Medical Officer) sold 19,682 shares of Heartflow, Inc. (HTFL) at $50.15 ($0.99M total) on 2026-09-18 under a Rule 10b5-1 trading plan.
1 min readBiotech Stocks At 52-Week Highs - HSCS +7%, FRNM +5%, VOGX, HTFL, HALO
Several biotech stocks reached 52-week highs on September 18, 2026. Vogenx (VOGX) shares surged to $38.41, driven by positive clinical trial results. HeartSciences (HSCS) rose 7% to $5.21, while HeartFlow (HTFL) increased 2% to $52.22. Freenome (FRNM) gained 5% to $17.25, and Halozyme (HALO) hit $112.66 after announcing a $1.3B offering.
4 min readHeartflow CFO Verghese sells over $1.2 million in company stock
HeartFlow CFO Vikram Verghese sold 24,345 shares worth $1.23M in two transactions, under a 10b5-1 plan, with shares trading near 52-week high. HeartFlow reported Q2 2026 revenue of $64.1M, up 48% YoY, and narrowed loss. Stifel raised its price target to $45, maintaining a Buy rating.
1 min readVerghese Vikram sold $1.2M of HTFL
Verghese Vikram (Chief Financial Officer) sold 24,345 shares of Heartflow, Inc. (HTFL) at an average of $50.55 ($50.11–$50.75, $1.23M total) across 2 trades over 2026-09-17 to 2026-09-18 under a Rule 10b5-1 trading plan.
1 min readHeartflow CFO Vikram Verghese sells $1.75M in stock
HeartFlow CFO Vikram Verghese sold $1.75M in shares from September 11-15, 2026, under a 10b5-1 plan. Shares sold at $50.012-$50.2381 each. HeartFlow's stock is near its 52-week high, up 130% in six months. The company reported 43% revenue growth but remains unprofitable. Q2 2026 revenue was $64.1M, beating estimates. Stifel raised its price target to $45 with a Buy rating.
1 min readVerghese Vikram sold $1.8M of HTFL
Verghese Vikram (Chief Financial Officer) sold 34,975 shares of Heartflow, Inc. (HTFL) at an average of $50.08 ($50.01–$50.24, $1.75M total) across 3 trades over 2026-09-11 to 2026-09-15 under a Rule 10b5-1 trading plan.
1 min readHeartflow (HTFL) CEO unloads 38,900 shares in planned stock sales
Heartflow (HTFL) CEO John C.M. Farquhar sold 38,900 shares of common stock in two transactions on September 10 and 11, 2026, under a Rule 10b5-1 trading plan. The sales totaled $1.82M, with prices ranging from $45.43 to $50.00 per share. Farquhar now holds 321,914 shares directly.
1 min readFarquhar John C.M. sold $1.8M of HTFL
Farquhar John C.M. (Chief Executive Officer) sold 38,900 shares of Heartflow, Inc. (HTFL) at an average of $46.78 ($46.42–$50.00, $1.82M total) across 2 trades over 2026-09-10 to 2026-09-11 under a Rule 10b5-1 trading plan.
1 min readHeartflow (HTFL) officer moves to sell 4,593 shares
Heartflow (HTFL) officer Vikram Verghese plans to sell 4,593 shares worth $230,743.50, acquired via a stock option exercise on June 10, 2024. The sale will be conducted under Rule 144 through Fidelity Brokerage Services LLC. As of September 14, 2026, 86,953,627 shares of common stock were outstanding.
1 min read
HTFL Soars After Q2 Beat And Raised 2026 Revenue Outlook
HeartFlow (HTFL) stock rose 9.63% after Q2 earnings beat and raised 2026 revenue outlook. Q2 revenue was $64.08M with 80.1% gross margin, but -55.8% profit margin. Company has strong liquidity with $162.55M cash and low debt. Analysts see near-term support at $46-$47 and resistance at $54-$56, with a 12-month target of $60 if growth continues.
2 min read